In the relentless pursuit of modern medicine, Targeted Protein Degradation (TPD) has emerged as a revolutionary therapeutic strategy, offering new hope for the treatment of numerous diseases. Traditional small-molecule inhibitors mainly actRead More…
Introduction Proteolysis-targeting chimeras are a new class of small molecules that provide alternative ways to discover drugs by leading target proteins to be selectively destroyed. In contrast to conventional inhibitors that only suppressRead More…
Targeting tumor cell apoptosis and angiogenesis Apoptosis (or programmed cell death) is an evolutionarily conservative process that maintains tissue homeostasis under cellular stress, DNA damage and immune surveillance. However, cancer cells canRead More…
The occurrence and development of cancer is a complex process, which is characterized by continuous proliferation signals, avoidance of growth inhibitors, resistance to cell death, induction of angiogenesis, activation of invasion andRead More…
Recently, Pfizer and Arvinas jointly announced that they have reached an agreement to co-develop and promote the Protein Degrader protein degrader ARV-471. Arvinas will receive $650 million in upfront payments and potentiallyRead More…
Advantages of Protein Degrader technology Through Protein Degrader technology, it is possible to develop drugs against undruggable or difficult-to-drug targets of traditional inhibitors. The Protein Degrader does not rely on theRead More…
Over the past decade, major changes have taken place in the field of drug targets. Although traditional targets (such as kinases and G-protein-coupled receptors) are still the main stream, the focus isRead More…